Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 36Nivolumab 32Bevacizumab 13Sunitinib 10Ipilimumab 10aldesleukin 7Interleukin-2 7Axitinib 7lenvatinib 6cabozantinib 6Paclitaxel 6Everolimus 6Docetaxel 6Cyclosporine 6Cyclophosphamide 6fludarabine phosphate 5Sorafenib 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5fludarabine 4cemiplimab 4belzutifan 4Whole-Body Irradiation 4Radiosurgery 4Interferon-alpha 4Cetuximab 4durvalumab 3bempegaldesleukin 3avelumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Renal Cell × Photons × Clear all
NCT06432036 2026-06-05

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

Jonsson Comprehensive Cancer Center

Phase 1/2 Recruiting
25 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡